
Omeros (OMER) Stock Forecast & Price Target
Omeros (OMER) Analyst Ratings
Bulls say
Omeros Corp has demonstrated a positive financial trajectory, evidenced by an increase in other income to $2.1 million due to higher interest income from its larger cash balance, which supports ongoing operations and growth. The company is also preparing for the End-of-Phase 2 submission for its lead candidate narsoplimab, having shown a statistically significant survival advantage for treated patients, bolstering the clinical evidence for its development in complement-mediated diseases. Furthermore, Omeros is focusing on late-stage development planning amidst a competitive landscape for complement-targeting therapies, highlighting its commitment to advancing potentially transformative treatments in areas with significant unmet medical needs.
Bears say
Omeros Corporation has incurred substantial operating losses, with expectations of remaining unprofitable for several years, indicating significant financial instability. The company's recent decrease in research and development expenses, reflective of a reduction in clinical trials, suggests a cautionary approach as it faces challenges in funding and operational capabilities. There are concerns regarding the likelihood of FDA approval for narsoplimab, driven by an atypical development trajectory, insufficient clinical data, and a prolonged period without new clinical evidence since the Complete Response Letter (CRL).
This aggregate rating is based on analysts' research of Omeros and is not a guaranteed prediction by Public.com or investment advice.
Omeros (OMER) Analyst Forecast & Price Prediction
Start investing in Omeros (OMER)
Order type
Buy in
Order amount
Est. shares
0 shares